文献速递免疫规划

基于TB10.4与Ag85B的新型结核疫苗:现状及对良好实践的倡导

Novel tuberculosis vaccines based on TB10.4 and Ag85B: State-of-art and advocacy for good practices.
PubMed 文献 · Vaccine · 2025-03-02

结核病仍是重大健康挑战,卡介苗对成人保护效果有限。本文综述以TB10.4和Ag85B为靶抗原的候选疫苗理性设计,讨论二者在结核分枝杆菌毒力中的作用及生产挑战,并分析通过多糖与佐剂连接增强免疫原性的蛋白偶联策略及重组抗原蛋白与偶联物的分析方法。作者主张采用标准化程序和详细报告以提高生物结果的可重复性与合理性。

要点

  • 卡介苗广泛使用但对成人保护效果有限。
  • 综述聚焦TB10.4与Ag85B抗原的疫苗理性设计。
  • 蛋白与多糖、佐剂偶联可增强免疫原性。

核心结论

  • 使用标准化程序和详细报告进行蛋白生产与化学修饰,可提高生物结果的可重复性与合理性,从而最好地实现开发有效结核疫苗的目标。

研究设计与样本

  • 综述,聚焦靶向TB10.4和Ag85B抗原的疫苗候选理性设计。

主要发现

  • 综述讨论了TB10.4和Ag85B在结核分枝杆菌毒力中的作用及其生产中的挑战。
  • 综述考虑了将抗原与多糖和佐剂连接等多种增强免疫原性的蛋白偶联策略。
  • 综述考虑了表征重组抗原蛋白及其偶联物的最适分析方法。
  • 综述强调了开发包含特定多糖和蛋白组分的疫苗所面临的挑战。

临床怎么用

  • 作者主张在蛋白生产和化学修饰中采用标准化程序和详细报告。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tuberculosis (TB) has plagued humanity in numerous devastating forms for centuries and remains a significant health challenge. Mycobacterium tuberculosis (Mtb), the bacterium responsible for TB, was the leading cause of death among infectious agents until the COVID-19 pandemic emerged. Immunization with the bacillus Calmette-Guérin (BCG) vaccine is one of the primary strategies to mitigate the risk of TB. Despite its widespread use, the current BCG vaccine has limited efficacy, particularly in adults. This review focuses on the rational design of vaccine candidates targeting the antigens TB10.4 and Ag85B. The review discusses the roles of TB10.4 and Ag85B in the virulence of Mtb and notes challenges in their production. Additionally, various protein conjugation strategies to enhance immunogenicity, including linking these antigens to glycans and adjuvants, are considered, as well as the most appropriate analytical methods for characterizing recombinant antigenic proteins and their conjugates. Finally, the associated challenges in developing a vaccine encompassing specific glycans and protein components were highlighted. We claim that using standardized procedures and detailed reporting in protein production and chemical modification can improve the reproducibility and rationalization of biological results. By adhering to these guidelines, the goal of developing an effective vaccine against TB will be best achieved.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tengattini S, Bavaro T, Rinaldi F, et al. Novel tuberculosis vaccines based on TB10.4 and Ag85B: State-of-art and advocacy for good practices. Vaccine. 2025. PMID: 40031085. doi:10.1016/j.vaccine.2025.126932

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。